To the best of our knowledge, our results are the first to demonstrate that mutations in PTEN, a tumor-suppressor gene, are associated with decreased OS or increased spinal metastasis recurrence in a surgical cohort consisting entirely of prostate cancer patients who developed spinal metastases. Here, PTEN is linked to prostate carcinoma.